Sanofi

Elodie Barbagallo

Murielle Rinaldi-Carmona

Claude Vernhet

Pascale Roux

Carole Legeay

The subject of the present invention is compounds corresponding to the formula (I) in which: X represents a divalent (C-C)alkylene radical which is unsubstituted or substituted one or more times by an Alk group; Rrepresents a phenyl, a naphthyl, a pyridyl, a 1-benzothienyl or a 1,3-benzodioxolyl; Rrepresents a hydrogen atom, a halogen atom, an Alk group, an OAlk group or else a group chosen from &#x2014;S-Alk, &#x2014;SO-Alk, &#x2014;SO-Alk, &#x2014;CO&#x2014;N(R)-Alk, &#x2014;N(R)SO-Alk, &#x2014;N(R)CO-Alk, &#x2014;N(R)SO&#x2014;N(Alk); Rrepresents a hydrogen atom, a halogen atom, an Alk group or an OAlk group; Rrepresents a hydrogen atom or a (C-C)alkyl; Alk represents an unsubstituted or substituted (C-C)alkyl. Preparation process and therapeutic application. 

[object Object]

The present invention is related to novel substituted 1-benzylcinnolin-4(1H)-one derivatives having affinity for cannabinoid CBreceptors, their preparation and their therapeutic application.

Growing community of inventors

Paris, France

Elodie Barbagallo